Impact of genetic polymorphism of metabolic pathway of methotrexate and survival rate of mexican children will all




Lymphoma/*drug therapy/genetics, genetic polymorphisms, ATP-binding cassette transporter gene.


Background: Acute lymphoblastic leukemia (ALL) is a major cancer disease in Mexican pediatric population, were the genotype could affect the effectiveness of chemotherapy in which the methotrexate (MTX) is involved and consequently the time of disease free survival and overall survival. Objective: Determine the association of 10 genetic polymorphisms of the folate pathway: in cellular carriers (COL18A1, SLC19A1, ABCB1 and ABCC5) and in enzymes such as folylpolyglutamate synthetase (FPGS) and xanthine oxidase (XO), with survival of children with acute lymphoblastic leukemia. Methods: Thirtynine children with acute lymphoblastic leukemia from the State Cancer Center in Durango (Mexico) treated with MTX and 102 healthy controls, were qPCR analyzed for 10 polymorphisms in the folate pathway. During 5 years of follow up, the disease-free survival and overall survival rates were investigated in relation with their genotypes. Results: Four polymorphisms were not found in Hardy-Weinberg Equilibrium COL18A1 (rs2274808), ABCC5 (rs9838667 and rs3792585) and XO (rs170113685). Only XO (rs170113685) was associated with risk of being present in patients with ALL whose odds ratio was 9.771 (95% 4.974-19.196, p=0.001). The polymorphism rs1544105 for FPGS affected disease free survival and overall survival (Log Rank test p<0.05). Conclusion: Polymorphism (rs17011368) of XO showed risk association for acute lymphoblastic leukemia; likewise, an important association was found between carriers of the FPGS (rs1544105) and increased survival times of patients treated with methotrexate. Keywords: Methotrexate, XO, FPGS, survival, Precursor Cell Lymphoblastic Leukemia-
= 204 veces | PDF (ESPAÑOL (ESPAÑA))
= 128 veces|


Download data is not yet available.

Author Biographies



, Instituto Politécnico Nacional-CIIDIR


, Centro Estatal de Cancerología (CECAN) of SSA


, Instituto Politécnico Nacional-CIIDIR


, Universidad Autónoma de Baja California

Facultad de Medicina y Psicología, PhD

, Universidad Juárez del Estado de Durango (UJED)

Facultad de Medicina, Departamento de Fisiología


Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JR, et al. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res. 2007;67(18):8772-82.

Leclerc GJ, Sanderson C, Hunger S, Devidas M, Barredo JC. Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia. Leukemia research. 2010;34(12):1601-9.

Kudo M, Sasaki T, Ishikawa M, Hirasawa N, Hiratsuka M. Kinetics of 6-Thioxanthine Metabolism by Allelic Variants of Xanthine Oxidase. Drug Metab Pharmacokinet. 2010;25(4):361-6.

Kremer J. Methotrexate pharmacogenomics. Ann Rheum Dis. 2006;65(9):1121-3.

Crews KR, Zhou Y, Pauley JL, Howard SC, Jeha S, Relling MV, et al. Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. Cancer. 2010;116(1):227-32.

Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. British journal of haematology. 2009;146(5):489-503.

Mahajan VB, Olney AH, Garrett P, Chary A, Dragan E, Lerner G, et al. Collagen XVIII mutation in Knobloch syndrome with acute lymphoblastic leukemia. Am J Med Genet A. 2010;152A(11):2875-9.

Galbiatti AL, Castro R, Caldas HC, Padovani JA, Jr., Pavarino EC, Goloni-Bertollo EM. Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(6):3765-71.

Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. 2013;13:227–34.

Adema AD, Floor K, Smid K, Honeywell RJ, Scheffer GL, Jansen G, et al. Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus. 2014;3:732.

Brambila-Tapia AJL. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Inv Clin.


Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods in molecular biology. 2010;596:47-76.

Gregers J, Gréen H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, et al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015.

Haematology BSo. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia: BSH; 2006 [cited 2013 09].

Available from: http// Pui C, Pei D, Sandlund J, Ribeiro R, Rubnitz J, Raimondi S, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371-82.

d’Oncologia IC. SNPStats. Cataluña: ICO; 2006.

Zhao R, Goldman D. Folate and Thiamine Transporters mediated by Facilitative Carriers (SLC19A1-3 and SLC46A1) and Folate Receptors. Molecular aspects of medicine. 2013;34:1-23.

Lima A, Bernardes M, Sousa H, Azevedo R, Costa L, Ventura F, et al. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics. 2013;15(6):807-20.



How to Cite

Fausto Leonardo, Ismael, Aarón, Verónica, Horacio, & María Cristina. (2016). Impact of genetic polymorphism of metabolic pathway of methotrexate and survival rate of mexican children will all. Vitae, 22(3), 177–187.



Pharmacology and Toxicology

Similar Articles

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 > >> 

You may also start an advanced similarity search for this article.